A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased DonorBone Marrow Transplantation for Patients with Hematologic Malignancies (PRESERVE I)


NCT Number:



Study Status:






The purpose of the study is to learn if a transplant using bone marrow recovered from deceased organ and tissue donors is safe and effective in patients undergoing bone marrow transplant (BMT). This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard of care for transplant. Bone marrow cells from a deceased organ and tissue donor in your transplant is the investigational treatment in this study and has not yet been approved by the Food and Drug Administration (FDA). This study is the first in human study that will use deceased donor bone marrow for the treatment of hematological malignancies.

Are you Eligible? (Inclusion Criteria)

  • Patient Criteria: - Must be at least 18 years old and less than 70 years old - Must require allogeneic HCT per the discretion of the treating physician - Diagnosed with acute leukemia

Specialty Area(s)

Blood and Marrow Stem Cell Transplantation, Leukemia, Acute Lymphocytic leukemia, Acute Myeloid Leukemia, Immunotherapy

Principal Investigator

Profile Headshot
  • Director, Adult Blood and Marrow Transplantation Program, Columbia University Medical Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032